Long-acting cabotegravir for prevention: hope versus reality. - National Genomics Data Center (CNCB-NGDC)

Advanced Search

Long-acting cabotegravir for prevention: hope versus reality.

Sheena McCormack, Marta Boffito

Author Information

Sheena McCormack: Medical Research Council Clinical Trials Unit at UCL, London WC2B 6NH, London; Imperial College London, London, UK; Chelsea and Westminster Hospital, London, UK. Electronic address: s.mccormack@ucl.ac.uk.
Marta Boffito: St Stephen's AIDS Trust, London, UK; Imperial College London, London, UK; Chelsea and Westminster Hospital, London, UK.

PMID: 28546089 DOI: 10.1016/S2352-3018(17)30074-7

No abstract text available.

Anti-HIV Agents

HIV Infections

Humans

Pyridones

Anti-HIV Agents

Pyridones

cabotegravir

Journal Article Comment

Cabotegravir long-acting for HIV-1 prevention.Long-acting injectable cabotegravir for the prevention of HIV infection.Long-Acting Cabotegravir for HIV/AIDS Prophylaxis.The hope and reality of long-acting hemophilia products.Formulation and pharmacology of long-acting cabotegravir.Long-Acting Cabotegravir for HIV Prevention: Issues of Access, Cost, and Equity.Long-acting injectable cabotegravir for PrEP: A game-changer in HIV prevention?Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.Long-acting cabotegravir PrEP: a time for cautious optimism.Microbicides for HIV prevention: reality or hope?

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.